MUMBAI, India, Oct. 26 -- Intellectual Property India has published a patent application (202541036631 A) filed by Pragadeeshwaran Shanmuganandham Sarangapani; Kaviya Gurunathan; Sakthi Priya Kumar; and Jayavel Karthick Panner Selvam on April 16, 2025, for Personalized And Computational Approach For Multi-Target Drug Design And Delivery In Major Depressiv.
Inventors include Pragadeeshwaran Shanmuganandham Sarangapani; Kaviya Gurunathan; Sakthi Priya Kumar; and Jayavel Karthick Panner Selvam.
The application for the patent was published on October 23, 2026, under issue no. 43/2026.
Abstract: Persistent Depressive Disorder (POD) IS a complex, chronic mental health condition characterized by persistent low mood and impaired daily functioning. Conventional pharmacological treatments, primarily based on monoaminergic modulation, often fail to deliver consistent and effective results across the diverse POD patient population due to underlying biological heterogeneity. Addressing this gap, the _present invention offers a personalized therapeutic strategy that stratifies patients into distinct subtypes based on genomic, transcriptomic, and proteomic biomarkers, enal)ling precision-targeted treatment. Utilizing patient-specific molecular data,· the invention identifies key dysregulated pathways-such as inflammation, oxidative stress, and impaired neurogenesis-and applies computational network analysis to reveal central hub genes involved in disease progression. A novel focus is placed on the Hedgehog (Hh) signaling pathway, an emerging therapeutic target linked to neuroiriflammatory modulation in depressive disorders . . o Building on 'the molecular classification, the invention advances a multi-target drug design approach tailored to the unique pathophysiological profiles of each POD subtype. This involves the use of Protein-Protein Interaction (PPI) network modeling, molecular docking, ADMET screening, and QSAR analysis to prioritize bioactive compounds capable of modulating multiple disease-relevant targets simultaneously.· Unlike· conventional single-target antidepressants, the proposed formulations are rationally engineered to engage a network of dysregulated proteins and signaling cascades, improving both efficacy and therapeutic coverage. In addition, the _integration of the Hh signaling.-pathway as a strategic ri'ode in drug design enhances the novelty and speci'ficity · of this invention, addressing previously unrecognized ~olecular contributors. to treatment-resistant depression. This design pipeline is entirely in silico-driven, reducing cost and expediting the preclinical validation process . o To ensure optimal drug bioavailability and central nervous system (CNS) targeting, the invention incorporates a nanoparticle-based drug delivery system that effectively crosses the blood-brain barrier (BBB). Utilizing simulation platforms·Iike NanoDDSimulator and CellDesigner, nanoparticles are engineered for controlled,·. sustained release and _ . . functionalized to enhance BBB penetration. These nanocarriers are optimized for size, Page.11 of 12 (p-~-T!=NT !"'!!=!= Tr !i: -·,~·-·-------~---- .. ------- 1.?.11· (0 ..... -C)) C) Ill D.. C)) -1- N E.... 0 -LL. ..... M (0 (0 M 0 ..... -::1' Lt) N 0 ~ en .e..n.. CIO !:2 Lt) N. 0 ~.... . c. surface charge, and ligand modifications, allowing precise delivery of the multi-target drugs to the brain with minimal systemic toxicity. The combination of precision drug design and advanced delivery mechanisms ensures higher therapeutic. efficacy, reduced side effects, and improved patient adherence. This invention thus represents a paradigm shift in POD treatment, merging personalized medicine, systems pharmacology, and nanotechnology into a unified, clinically translatable platform. The framework can further be extended to other neuropsychiatric disorders, highlighting its· broad industrial · and therapeutic applicability.
Disclaimer: Curated by HT Syndication.
